Home › Funds › Atle Fund Management AB › BSX
Atle Fund Management AB position in BSX
BOSTON SCIENTIFIC CORP · Health Care
Atle Fund Management AB reported holding 130,622 shares of BSX (BOSTON SCIENTIFIC CORP) in its Q3 2026 13F filing — a position valued at US$5.7M, representing 1.53% of its reported portfolio and ranking #25 among its reported holdings. Atle Fund Management AB has disclosed BSX holdings in 12 of the last 12 reported quarters, going back to Q4 2023.
Last updated: 2026-11-12 · Source: SEC EDGAR Form 13F-HR
How Atle Fund Management AB's BSX position evolved
Atle Fund Management AB first disclosed a stake in BSX in Q4 2023 at 64,806 shares (US$3.7M). The position peaked in Q4 2024 at 154,222 shares, worth US$13.8M. Across 12 filings, Atle Fund Management AB increased the stake 5 time(s), trimmed it 5 time(s) and left it unchanged 1 time(s). The most recent filing (Q3 2026) shows 130,622 shares valued at US$5.7M — a reduction of -15,759 shares quarter over quarter.. Notable position changes include a 45% increase in Q4 2024 (shares rose 13% over the following quarter), a 63% trim in Q1 2026 (shares fell 32% over the following quarter), a 262% increase in Q2 2026 (shares rose 2% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2023 | 64.81K | $3.75M | New |
| Q1 2024 | 77.40K | $5.30M | Add |
| Q2 2024 | 106.56K | $8.21M | Add |
| Q3 2024 | 106.17K | $8.90M | Hold |
| Q4 2024 | 154.22K | $13.83M | Add |
| Q1 2025 | 132.27K | $13.34M | Reduce |
| Q2 2025 | 126.19K | $13.55M | Reduce |
| Q3 2025 | 86.68K | $898.42K | Reduce |
| Q4 2025 | 108.68K | $10.36M | Add |
| Q1 2026 | 40.43K | $8.84M | Reduce |
| Q2 2026 | 146.38K | $6.25M | Add |
| Q3 2026 | 130.62K | $5.70M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About BSX and 13F data
BSX (BOSTON SCIENTIFIC CORP) is a Health Care company. 19 other funds we track also report a position in BSX — the largest reported positions include PRIMECAP MANAGEMENT CO/CA/ (US$2.16B), D. E. Shaw & Co (US$1.16B), Janus Henderson Group (US$1.04B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding BSX
- PRIMECAP MANAGEMENT CO/CA/ 50.52M sh · $2.16B · Q2 2026
- D. E. Shaw & Co 27.27M sh · $1.16B · Q2 2026
- Janus Henderson Group 16.50M sh · $1.04B · Q1 2026
- Arrowstreet Capital 23.29M sh · $994.18M · Q2 2026
- Bollard Group LLC 18.42M sh · $786.20M · Q2 2026
More on Atle Fund Management AB
FAQ
How long has Atle Fund Management AB held BSX?
Atle Fund Management AB has disclosed BSX holdings in 12 of the last 12 reported quarters, going back to Q4 2023.
What is Atle Fund Management AB's current position in BSX?
As of Q3 2026, Atle Fund Management AB holds 130.62K shares of BSX (BOSTON SCIENTIFIC CORP), valued at $5.70M, representing 1.53% of its reported portfolio and ranking #25.
Has Atle Fund Management AB been buying or selling BSX?
In the latest 13F filing (Q3 2026), Atle Fund Management AB reduced its position in BSX. The position peaked in Q4 2024 at 154.22K shares.
Which other funds hold BSX?
Other major institutional holders of BSX include PRIMECAP MANAGEMENT CO/CA/, D. E. Shaw & Co, Janus Henderson Group, among 19 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.